Innovent Biologics (HK:1801) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Innovent Biologics has announced that its TYVYT® (sintilimab injection) in combination with ELUNATE® (fruquintinib) has received conditional approval from China’s National Medical Products Administration for treating advanced endometrial cancer. This marks the eighth approval for TYVYT®, highlighting its expanding role in cancer treatment. With this approval, Innovent aims to offer new hope to patients with limited options, reinforcing its position in the immunotherapy market.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
